BTOG 2024 | Is there a role for radiotherapy in extensive-stage SCLC?

Clive Peedell, MD, James Cook University Hospital, Middlesbrough, UK discusses a debate he chaired at BTOG 2024 on the role of radiotherapy in small cell lung cancer (SCLC), particularly in extensive stage disease. Professors Corin Fevre Finn and Samreen Ahmed engaged in a discussion on the relevance of radiotherapy alongside the advent of immunotherapy. While acknowledging the importance of radiotherapy, the consensus leaned towards a more individualized approach tailored to patient needs. Although prophylactic cranial radiation (PCI) remains standard for some patients, there’s growing consideration for MRI surveillance as an alternative. However, limited access to frequent MRI scans poses challenges. Dr Peedell emphasizes that thoracic radiotherapy’s role in residual thoracic disease post-chemo-immunotherapy requires further investigation through ongoing trials, despite the general agreement on its continued relevance. This interview took place at the BTOG 2024 congress in Belfast, UK.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.